OmniAb expects $25M milestone payment from Janssen after first US commercial sale of TECVAYLI

OmniAb, Inc.

Janssen notified OmniAb that first US commercial sale of TECVAYLI (teclistamab) occurred, triggering $25M milestone.
OmniAb expects to receive the $25M payment and recognize $25M milestone revenue in Q4 2022.
Milestone arises from licensing agreement between OmniAb and an affiliate of Janssen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.